These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
346 related articles for article (PubMed ID: 6539859)
1. Behavioural and biochemical alterations in the function of dopamine receptors following repeated administration of L-DOPA to rats. Hall MD; Cooper DR; Fleminger S; Rupniak NM; Jenner P; Marsden CD Neuropharmacology; 1984 May; 23(5):545-53. PubMed ID: 6539859 [TBL] [Abstract][Full Text] [Related]
2. Behavioural and biochemical changes following chronic administration of L-dopa to rats. Pycock C; Dawbarn D; O'Shaughnessy C Eur J Pharmacol; 1982 Apr; 79(3-4):201-15. PubMed ID: 7201400 [TBL] [Abstract][Full Text] [Related]
3. Dopamine D2 receptors and dopamine metabolism. Relationship between biochemical and behavioural effects of substituted benzamide drugs. Magnusson O; Fowler CJ; Köhler C; Ogren SO Neuropharmacology; 1986 Feb; 25(2):187-97. PubMed ID: 2939362 [TBL] [Abstract][Full Text] [Related]
4. Cerebral dopamine function in rats following withdrawal from one year of continuous neuroleptic administration. Clow A; Theodorou A; Jenner P; Marsden CD Eur J Pharmacol; 1980 May; 63(2-3):145-57. PubMed ID: 6103814 [TBL] [Abstract][Full Text] [Related]
5. The central aromatic amino acid DOPA decarboxylase inhibitor, NSD-1015, does not inhibit L-DOPA-induced circling in unilateral 6-OHDA-lesioned-rats. Treseder SA; Rose S; Jenner P Eur J Neurosci; 2001 Jan; 13(1):162-70. PubMed ID: 11135014 [TBL] [Abstract][Full Text] [Related]
6. The selective dopamine D2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions. Ogren SO; Hall H; Köhler C; Magnusson O; Sjöstrand SE Psychopharmacology (Berl); 1986; 90(3):287-94. PubMed ID: 2947255 [TBL] [Abstract][Full Text] [Related]
7. Possible anomalous behaviour of apomorphine in relation to other dopamine receptor agonists. Feenstra MG; Goedemoed JH; Rollema H; Horn AS J Pharm Pharmacol; 1983 Jul; 35(7):471-3. PubMed ID: 6136595 [No Abstract] [Full Text] [Related]
8. Striatal dopamine receptor sensitivity after subchronic fencamfamine in the rat. Scavone C; De Lucia R; Bernardi MM; Aizenstein ML Eur J Pharmacol; 1985 May; 112(1):11-6. PubMed ID: 4040467 [TBL] [Abstract][Full Text] [Related]
9. Combined administration of direct dopamine receptor agonists and L-dopa does not interfere with utilization of exogenous L-dopa in rat corpus striatum. Globus M; Melamed E Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(2-3):211-5. PubMed ID: 6310691 [TBL] [Abstract][Full Text] [Related]
10. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease. Schneider MB; Murrin LC; Pfeiffer RF; Deupree JD Clin Neuropharmacol; 1984; 7(3):247-57. PubMed ID: 6435870 [TBL] [Abstract][Full Text] [Related]
11. Striatal dopamine receptors become supersensitive while rats are geven trifluoperazine for six months. Clow A; Jenner P; Theodorou A; Marsden CD Nature; 1979 Mar; 278(5699):59-61. PubMed ID: 570253 [No Abstract] [Full Text] [Related]
12. Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine. Breese GR; Baumeister AA; McCown TJ; Emerick SG; Frye GD; Crotty K; Mueller RA J Pharmacol Exp Ther; 1984 Nov; 231(2):343-54. PubMed ID: 6149306 [TBL] [Abstract][Full Text] [Related]
13. Neurochemical and behavioral effects of acute and chronic treatment with apomorphine in rats. Rowlett JK; Mattingly BA; Bardo MT Neuropharmacology; 1991 Feb; 30(2):191-7. PubMed ID: 1903190 [TBL] [Abstract][Full Text] [Related]
14. SCH 23390 may alter dopamine-mediated motor behaviour via striatal D-1 receptors. Boyce S; Kelly E; Davis A; Fleminger S; Jenner P; Marsden CD Biochem Pharmacol; 1985 May; 34(10):1665-9. PubMed ID: 2988552 [TBL] [Abstract][Full Text] [Related]
17. Alterations in different populations of striatal dopamine receptors produced by 18 months continuous administration of cis- or trans-flupenthixol to rats. Murugaiah K; Fleminger S; Hall MD; Theodorou A; Jenner P; Marsden CD Neuropharmacology; 1984 Jun; 23(6):599-609. PubMed ID: 6540376 [TBL] [Abstract][Full Text] [Related]
18. Alterations in cerebral dopamine function caused by administration of cis- or trans-flupenthixol for up to 18 months. Murugaiah K; Theodorou A; Jenner P; Marsden CD Neuroscience; 1983 Nov; 10(3):811-9. PubMed ID: 6685826 [TBL] [Abstract][Full Text] [Related]
19. Changes in rat striatal dopamine turnover and receptor activity during one years neuroleptic administration. Clow A; Theodorou A; Jenner P; Marsden CD Eur J Pharmacol; 1980 May; 63(2-3):135-44. PubMed ID: 6103813 [TBL] [Abstract][Full Text] [Related]
20. Persistent increase in striatal dopamine stimulated adenylate cyclase activity persists for more than 6 months but disappears after 1 year following withdrawal from 18 months cis-flupenthixol intake. Murugaiah K; Fleminger S; Theodorou A; Jenner P; Marsden CD Biochem Pharmacol; 1983 Sep; 32(17):2495-9. PubMed ID: 6684429 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]